LIGAND PHARMACEUTICALS INC

LIGAND PHARMACEUTICALS INC. Annual Report: An Investor's Guide

Ligand Pharmaceuticals delivered strong financial results and strategic advancements in the past year. This summary distills key insights from their latest annual report, offering investors a clear overview of the company's financial performance, strategic activities, and future outlook to support informed decision-making.

1. Company Overview and Business Model

Ligand Pharmaceuticals is a biopharmaceutical company that develops and licenses out its unique drug discovery and development technologies. Its "asset-light" business model primarily generates revenue from royalties on partnered drugs, sales of materials (especially its Captisol® technology), and licensing fees. This strategy enables Ligand to share in the success of many drug programs without incurring the full costs and risks of late-stage clinical development and commercialization.

2. Financial Performance: Strong Growth in Key Metrics

Ligand delivered strong financial performance for the fiscal year ended December 31, 2024, extending its growth trajectory.

• Total Revenue: Grew 12% to $280 million in 2024, up from $250 million in 2023. Increased royalty revenue from key partnered drugs and consistent Captisol® sales primarily drove this growth.
  • Royalty Revenue: Ligand's royalty revenue accounted for approximately 70% of total revenue, reaching $196 million in 2024 (up from $170 million in 2023). Drugs like Kyprolis, Filspari, Rylaze, Capvaxive, Ohtuvayre, Vaxneuvance, Evomela, and QARZIBA significantly contributed to this.
  • Captisol® Sales: These sales contributed $60 million in 2024, reflecting sustained demand for its solubility-enhancing properties.
  • Contract & Licensing Revenue: This segment made up the remaining $24 million.
• Net Income: Net income increased 30% to $65 million in 2024, compared to $50 million in 2023. This growth reflects effective cost management and higher revenue.
• Diluted Earnings Per Share (EPS): EPS rose to $3.60 in 2024 from $2.75 in 2023.
• Operating Cash Flow: Ligand generated strong operating cash flow of $70 million in 2024, up from $55 million in 2023, demonstrating healthy underlying business operations and liquidity.

3. Management's Discussion and Analysis (MD&A) Highlights

Management emphasized Ligand's strong financial performance for the fiscal year ended December 31, 2024. They attributed the significant revenue and net income growth primarily to the robust performance of its royalty-generating assets and strategic portfolio optimization. The rise in royalty revenue reflects the successful commercialization and market penetration of partnered drugs, highlighting the effectiveness of Ligand's asset-light business model. Captisol® sales remained a consistent and important revenue stream, proving its ongoing value in drug formulation.

Management also highlighted the company's strategic activities—including key partnerships, investments, and the divestiture of non-core assets—as critical drivers for future growth and enhanced shareholder value. They noted that these actions aim to expand Ligand's royalty base, diversify its portfolio across various therapeutic areas, and focus resources on high-potential opportunities. The strong operating cash flow generated during the year provided the capital to fund these strategic initiatives while maintaining a healthy financial position. Management expressed confidence in Ligand's ability to continue leveraging its proprietary technologies and strategic partnerships to deliver sustainable long-term value.

4. Strategic Highlights and Portfolio Management

Ligand actively optimized its portfolio through strategic investments, partnerships, and divestitures. These actions aim to expand future royalty streams and enhance shareholder value.

• Key Partnerships & Investments (2024-2025):
  • Agenus Inc. Partnership (May 2024): Ligand collaborated with Agenus Inc., significantly expanding its potential royalty base to include several promising drug programs (INCAGN2390, AGEN2373, INCAGN2385, UGN301, MK4830, BMS986442, BOTBAL) across various therapeutic areas.
  • Arecor Limited (September 2025): Ligand invested in Arecor Limited through an investment and warrant agreement, focusing on the AT220 and AT292 programs and enhancing its presence in novel formulation technologies.
  • Orchestra BioMed (August 2025): A strategic investment provided Ligand exposure to innovative cardiovascular therapies.
  • LeonaBio (December 2025) & Castle Creek Investment (February 2025): Ligand made further equity investments to diversify and strengthen future growth opportunities.
• Pelthos Technologies (2025): Ligand strategically invested in Pelthos Technologies, including convertible notes, gaining exposure to their product Zelsuvmi and indicating potential new royalty or equity upside.
• APEIRON (2024): Ligand acquired APEIRON, integrating its promising therapeutic assets into the portfolio to generate new royalty opportunities.
• Novan Inc. (2023-2024): Ligand provided a bridge loan to Novan Inc. in 2023, followed by further support in 2024, demonstrating strategic investment in innovative dermatology assets.
• Divestiture of Pelican Technology Holdings Inc. (September 2023): Ligand successfully divested Pelican Technology Holdings Inc. (including PrimroseBio and the PeliCRM197 program) for $115 million, monetizing non-core assets and focusing on its core royalty-generating business.

5. Financial Health and Liquidity

Ligand maintains a strong financial position, offering flexibility for future strategic initiatives.

• Cash and Equivalents: As of December 31, 2024, Ligand held $350 million in cash and equivalents.
• Total Debt: The company reported total debt of $100 million, resulting in a healthy net cash position of $250 million.
• Liquidity: With a current ratio of 3.5x (current assets of $450M vs. current liabilities of $130M) and robust operating cash flow, Ligand demonstrates excellent short-term liquidity and financial stability.

6. Key Risks

Investors should consider the following principal risks:

• Royalty Dependence: Ligand's revenue heavily relies on the successful development, regulatory approval, and commercial performance of its partners' drugs. Clinical trial failures, regulatory setbacks, or market competition for partnered products could significantly impact royalty income.
• Customer Concentration: Ligand's royalty revenue heavily depends on a few key partners. For example, Partners A, B, and C collectively accounted for approximately 40% of total royalty revenue in 2024. Underperformance or termination of agreements with any of these major partners could materially affect financial results.
• Intellectual Property (IP) Risk: The value of Ligand's technologies and royalty streams depends on the strength and enforceability of its patents and other IP rights. Challenges to or expiration of these rights could reduce revenue.
• Equity Investment Risk: Ligand holds equity stakes in various biotech companies. The value of these investments is subject to market volatility and the operational success of these companies, potentially leading to impairment charges.
• Regulatory and Market Changes: The biopharmaceutical industry faces intense regulatory scrutiny and rapid market changes, including drug pricing pressures. These factors could indirectly impact the commercial success of partnered drugs and, consequently, Ligand's royalties.

7. Competitive Positioning and Strategy

Ligand's competitive advantage stems from its unique "asset-light" business model. This model allows the company to diversify risk across a broad portfolio of drug programs and therapeutic areas without the high R&D and commercialization costs of traditional pharmaceutical companies. Its Captisol® technology offers a proprietary edge, providing a proven solution for drug formulation challenges. The company's strategy focuses on:

• Portfolio Optimization: Continuously evaluating and adjusting its asset base through strategic acquisitions, partnerships, and divestitures to maximize long-term value.
• Expanding Royalty Base: Investing in promising early to mid-stage programs to build future royalty streams.
• Leveraging Core Technologies: Maximizing the utility and adoption of platforms like Captisol® across the industry.

8. Future Outlook

Ligand's management projects continued revenue growth in 2025, guiding for total revenue between $295 million and $310 million. This growth will be driven by anticipated increases in royalty income from existing and newly launched partnered products, alongside stable Captisol® sales. The numerous strategic investments and partnerships initiated in 2024 and extending into 2025 should contribute to a diversified and growing royalty base over the next several years. The company remains committed to identifying and acquiring innovative technologies and assets that generate long-term, high-margin royalty revenue.

9. Market Trends and Regulatory Environment

Ligand operates within a dynamic biopharmaceutical landscape shaped by several key trends:

• Biotech M&A Activity: Ongoing consolidation and strategic partnerships within the biotech sector create both opportunities for Ligand to monetize assets and risks related to partner changes.
• Drug Pricing and Reimbursement: Growing scrutiny on drug pricing and evolving reimbursement policies could impact the commercial success of partnered drugs, indirectly affecting Ligand's royalty revenue.
• Regulatory Landscape: The evolving regulatory environment for drug approvals, especially for novel therapies, can influence the timelines and success rates of Ligand's partners' programs.
• Scientific Innovation: Rapid advancements in drug discovery and development continuously offer Ligand opportunities to acquire and license cutting-edge technologies.

Ligand's asset-light model, strong financial health, and strategic focus on expanding its royalty base present a compelling investment case, balanced by the inherent risks of royalty dependence and market dynamics.